RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Provention Bio - Stock

Provention Bio Stocks 2024

Provention Bio Stocks

74.72 M

Ticker

PRVB

ISIN

US74374N1028

WKN

A2JRLW

In 2024, Provention Bio had 74.72 M outstanding stocks, a 0% change from the 74.72 M stocks in the previous year.

The Provention Bio Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e74.72
2028e74.72
2027e74.72
2026e74.72
2025e74.72
2024e74.72
2023e74.72
202274.72
202163.1
202052.46
201940.75
201833.88
201733.88
201633.88

Provention Bio shares outstanding

The number of shares was Provention Bio in 2023 — This indicates how many shares 74.723 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Provention Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Provention Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Provention Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Provention Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Provention Bio Aktienanalyse

What does Provention Bio do?

Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Provention Bio's Shares Outstanding

Provention Bio's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Provention Bio’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Provention Bio’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Provention Bio’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Provention Bio Stock

How many stocks are there of Provention Bio?

The current number of stocks of Provention Bio is 74.72 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Provention Bio are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Provention Bio evolved in recent years?

The number of shares of Provention Bio has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Provention Bio as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Provention Bio?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Provention Bio pay?

Over the past 12 months, Provention Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Provention Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Provention Bio?

The current dividend yield of Provention Bio is .

When does Provention Bio pay dividends?

Provention Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Provention Bio?

Provention Bio paid dividends every year for the past 0 years.

What is the dividend of Provention Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Provention Bio located?

Provention Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Provention Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Provention Bio from 7/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did Provention Bio pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Provention Bio in the year 2023?

In the year 2023, Provention Bio distributed 0 USD as dividends.

In which currency does Provention Bio pay out the dividend?

The dividends of Provention Bio are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Provention Bio stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Provention Bio

Our stock analysis for Provention Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Provention Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.